Schindhelm Roger K, van Marwijk Kooy M Rien, Coenen Jules L L M, Huijgens Peter C, Kuiper-Kramer P A Ellen
Isala klinieken, Klinisch Chemisch Laboratorium, Zwolle, The Netherlands.
Ned Tijdschr Geneeskd. 2010;154:A1520.
The criteria for the diagnosis of chronic lymphocytic leukaemia (CLL) have recently been changed, with the absolute number of monoclonal B cells instead of the total number of lymphocytes now important. CLL is diagnosed when the number of monoclonal B cells with the characteristic CLL phenotype in peripheral blood exceeds 5 x 10(9)/l; fewer than 5 x 10(9)/l of monoclonal B cells with the characteristic CLL phenotype present in peripheral blood leads to a diagnosis of monoclonal B-cell lymphocytosis (MBL): a new diagnostic entity. The prevalence of MBL is estimated to be 3% and has a relatively mild course with a progression rate from MBL to CLL of 1-2% per year. After a single evaluation by a haematologist to exclude lymphadenopathy, organomegaly and infection as causes of the lymphocytosis, patients with MBL need only be evaluated once annually by their general practitioner for measurement of the blood lymphocyte count and referral in case of progression.
慢性淋巴细胞白血病(CLL)的诊断标准最近有所改变,现在重要的是单克隆B细胞的绝对数量而非淋巴细胞总数。当外周血中具有特征性CLL表型的单克隆B细胞数量超过5×10⁹/L时可诊断为CLL;外周血中具有特征性CLL表型的单克隆B细胞数量少于5×10⁹/L则诊断为单克隆B细胞淋巴细胞增多症(MBL):一种新的诊断实体。MBL的患病率估计为3%,病程相对较轻,每年从MBL进展为CLL的发生率为1%至2%。在血液科医生进行单次评估以排除淋巴结病、器官肿大和感染作为淋巴细胞增多的原因后,MBL患者只需每年由其全科医生评估一次,以测量血液淋巴细胞计数,并在病情进展时转诊。